scholarly journals Association of c/t polymorphism in the lrp5 gene with circulating follicle stimulating hormone in Caucasian postmenopausal women

2007 ◽  
pp. 735-739
Author(s):  
I Žofková ◽  
M Hill ◽  
K Zajíčková
Keyword(s):  
Postmenopausal Women ◽  
Sex Hormones ◽  
Restriction Analysis ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Mediating Role ◽  
Serum Lh ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

The LRP5 gene is believed to be primarily associated with bone metabolism via Wnt signaling. The latter pathway, however, appears to control various other systems outside the skeleton. To find the relationships of the LRP5 gene to serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the cohort of normal postmenopausal women, we identified the C/T (c.4037:A1330V) polymorphism in the LRP5 gene using a restriction analysis of the PCR product in a cohort of 165 untreated pre- and post-menopausal women. In a subset of 111 post-menopausal women we analyzed the association between the LRP5 genotype and serum levels of sex-hormones including FSH and LH. The distribution of CC, TC and TT genotypes of the C/T polymorphism in the whole group was 73.9 %, 23.6 % and 2.4 %, respectively, which is comparable with other Caucasian populations. As no TT homozygote was found in the group of post-menopausal women, serum sex-hormones were compared between CC and TC genotypes. Women with the CT allele combination had markedly higher serum FSH levels as compared to carriers of the CC genotype (p<0.004). No differences between these genotypes were found in serum LH levels as well as the circulating sex-steroids such as estradiol, testosterone, dehydroepiandrosterone and/or its sulphate, androstenedione and SHBG. To conclude, the LRP5 gene is associated with circulating FSH in normal post-menopausal women in the present study. The mediating role of subtle undetectable variations in estrogen levels is discussed. We did not find any relationship between the LRP-5 genotype and serum LH levels.

Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine

1983 ◽  
Vol 98 (3) ◽  
pp. 381-384 ◽  
Author(s):  
J. H. Livesey ◽  
H. K. Roud ◽  
M. G. Metcalf ◽  
R. A. Donald
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Urine Samples ◽  
Initial Value ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

First morning urine samples were collected from both menstruant and post-menopausal women and stored at −25 °C. Immunoreactive FSH disappeared from these samples (t½ = 30 days), ultimately stabilizing at about 20% of the initial value. The loss was more rapid at −20 °C and less rapid at −55 °C and +4°C. Immunoreactive LH was also lost from frozen urine, but more slowly than FSH. The addition of glycerol to urine (0·52 mol/l) stored at −25 °C prevented loss of immunoreactive FSH and LH for at least 105 days.

scholarly journals High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women

2021 ◽  
Vol 12 ◽  
Author(s):  
Qihang Li ◽  
Dongmei Zheng ◽  
Haiyan Lin ◽  
Fang Zhong ◽  
Jing Liu ◽  
...  
Keyword(s):  
Renal Function ◽  
Risk Factor ◽  
Renal Dysfunction ◽  
Clinical Chemistry ◽  
Follicle Stimulating Hormone ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

ObjectiveMenopause contributes to renal dysfunction in women, which is generally attributed to estrogen withdrawal. In addition to decreased estrogen level, serum follicle-stimulating hormone (FSH) level increases after menopause. This study investigated the association between high circulating FSH level and renal function in post-menopausal women.MethodsThis observational cross-sectional study included 624 pre-menopausal, 121 peri-menopausal, and 2540 post-menopausal women. The levels of female sex hormones were examined by chemiluminescence and indices of renal function were measured using a clinical chemistry analyzer. The post-menopausal women were grouped into quartiles according to serum FSH levels.ResultsRenal function progressively declined from pre-menopause to peri-menopause to post-menopause, which was accompanied by increasing serum FSH level. In post-menopausal women, serum creatinine level increased with increasing FSH quartile, which was accompanied by a decrease in estimated glomerular filtration rate (eGFR) (p for trend &lt;0.001); moreover, the prevalence of declined eGFR (&lt;90 ml/min/1.73 m2) and chronic kidney disease (CKD; eGFR &lt;60 ml/min/1.73 m2) increased (p for trend &lt;0.001). Even after adjusting for confounders, the odds ratios (ORs) of declined eGFR and CKD increased with increasing FSH quartiles in post-menopausal women. The ORs of declined eGFR (OR=2.19, 95% confidence interval [CI]: 1.63–2.92) and CKD (OR=10.09, 95% CI: 2.28–44.65) in the highest FSH quartile were approximately 2- and 10-fold higher, respectively, than in the lowest FSH quartile (p&lt;0.05). After stratifying post-menopausal women by median age (61 years), the OR for declined eGFR for each FSH quartile in the older group was higher than that for the corresponding FSH quartile in the younger group.ConclusionsA high circulating FSH level is an independent risk factor for renal dysfunction in women after menopause. Additionally, aging may aggravate the association of high FSH levels with reduced renal function in post-menopausal women.

CHANGES IN SERUM LEVELS OF FOLLICLE STIMULATING HORMONE AND LUTEINIZING HORMONE SHORTLY BEFORE AND AFTER PARTURITION IN RATS

1974 ◽  
Vol 75 (3) ◽  
pp. 491-496 ◽  
Author(s):  
Junichi Mori ◽  
Hiroshi Nagasawa ◽  
Reiko Yanai ◽  
Junji Masaki
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Sprague Dawley ◽  
Appreciable Change ◽  
Serum Lh ◽  
Sprague Dawley Rats ◽  
Before And After ◽  
Average Serum ◽  
Stimulating Hormone

ABSTRACT The sequence of changes in the serum levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from 2 days before to 24 h after parturition of primiparous Sprague-Dawley rats was investigated by radioimmunoassay. No appreciable change in average serum FSH levels was observed during 2 days before and 1 h after parturition. After this the levels increased gradually to show a peak at 7 h after parturition and then declined gradually until 24 h after parturition. However, the level at 24 h after parturition was still twice as high as that at parturition (0 h). The average serum LH levels which were low between 2 days before and 1 h after parturition, showed a peak at 7 h and decreased toward 13 h after parturition. The same levels as at parturition were maintained between 13 and 24 h after parturition. The time of surge of either FSH or LH was closely related to the time after parturition. There were some differences between FSH and LH in the patterns of sequence of changes in the serum levels near parturition.

scholarly journals Follicle-stimulating Hormone and Lipid Profile in Women Older than 55

2021 ◽  
Author(s):  
Wen Zhang ◽  
Yingchao Chen ◽  
Xian Zhang ◽  
Yi Chen ◽  
Bing Han ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Sex Hormones ◽  
High Probability ◽  
Metabolic Diseases ◽  
Follicle Stimulating Hormone ◽  
Regression Analyses ◽  
Menopausal Women ◽  
Low Hdl ◽  
Adjusted Model ◽  
Stimulating Hormone

Abstract Purpose. Follicle stimulating hormone (FSH) is associated with higher risks of metabolic syndrome and diabetes in menopausal women. We aimed to investigate whether FSH was associated with lipid profile in women older than 55 who were postmenopausal with a high probability.Methods. Our data were from Survey on Prevalence in East China for Metabolic Diseases and Risk Factors. 1795 women at the age of 55-89 were selected. Sex hormones and lipid profile were measured from morning serum. Linear and logistic regression analyses were used. Results. Lower FSH was associated with lower HDL-C, higher TG, TC/HDL-C ratio and LDL-C/HDL-C ratio (all P for trend<0.05), after adjusting for age and other sex hormones. Further adjustment for body mass index, diabetes and hypertension, the associations of FSH with lipid profile weakened, but the association of FSH quartiles with HDL-C and TC/HDL-C ratio was still significant (both P for trend<0.05). Compared with women in the highest FSH quartile, odds of low HDL-C (HDL-C <1.04mmol/L) in women in the lowest FSH quartile were 5.25 (95% confidence interval 1.60, 17.26) (P for trend <0.05) in fully adjusted model, and odds of TC≥6.22mmol/L, TG≥2.26mmol/L and LDL-C≥4.14mmol/L were not significant. LH did not show significant association with dyslipidemia.Conclusion. Lower FSH was associated with worse lipid profile in women older than 55. Diabetes, adiposity and hypertension mostly explained the association of FSH with TG and LDL-C/HDL-C ratio but only partially explained the associations of FSH with HDL-C and TC/HDL-C ratio.

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1994 ◽  
Vol 131 (3) ◽  
pp. 286-292 ◽  
Author(s):  
David Gonzalez-Barcena ◽  
Manuel Vadillo Buenfil ◽  
Emilo Garcia Procel ◽  
Laura Guerra-Arguero ◽  
Imelda Cardenas Cornejo ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Free Testosterone ◽  
Serum Levels ◽  
Routes Of Administration ◽  
Serum Lh ◽  
The Mean ◽  
Potent Antagonist ◽  
Normal Men ◽  
Stimulating Hormone

Gonzalez-Barcena D, Vadillo Buenfil M, Garcia Procel E, Guerra-Arguero L, Cardenas Cornejo I, Comaru-Schally AM, Schally AV. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of LH-RH, Cetrorelix (SB-75). Eur J Endocrinol 1994;131:286–92. ISSN 0804–4643 Cetrorelix (SB-75; [Ac-d-Nal(2)1, d-Phe(4Cl)2, d-Pal(3)3, d-Cit6, d-Ala10] luteinizing hormone-releasing hormone (LHRH)) is a new highly potent antagonist analog of LHRH containing the d-ureidoalkyl amino acid d-citrulline at position 6 and is free of allergenic effects. This study shows the inhibition of LH and follicle-stimulating hormone (FSH) release in normal men, postmenopausal women and patients with gonadal dysgenesis, using different doses and im, sc and iv routes of administration of SB-75. The mean serum levels of LH and FSH in normal men who received one single dose of 300 μg of SB-75 sc started to decline rapidly 1 h after its administration; the LH suppression was sustained for 14 h and that of FSH up to 24 h or longer as the samples were obtained only up to this time. The nadir for LH was reached at 14 h and that for FSH at 24 h or later after administration of the antagonist (p < 0.05). Serum levels of total and free testosterone decreased after the first hour and this inhibition was maintained for up to 14 h. The nadir for total testosterone was at 6 h and that for free testosterone was at 8 h (p < 0.001), corresponding to 56% and 60% of inhibition, respectively. In postmenopausal women, inhibition of the elevated basal serum LH and FSH levels occurred after a single injection of the antagonist analog SB-75 in doses of 75, 150, 300, 600 and 1200 μg using im, sc and iv routes of administration. The mean resting levels of serum LH and FSH showed a significant decrease for all doses and routes of administration of SB-75 (p < 0.01). Maximal inhibition was observed 6–12 h after administration. After administration of 300 μg of SB-75 sc every 12 h for 3 days, serum LH and FSH continued to be secreted but a marked decrease in the basal levels of both gonadotropins was observed. A fall in LH and FSH also was produced in patients with gonadal dysgenesis who were given 300 μg of SB-75. The nadir of serum LH was 61 ± 9.6% for the iv route and 58.5 ± 7.5% for the sc route (p < 0.01); for serum FSH it was 51 ± 7.5% and 48.5 ± 7.5% (p < 0.01), respectively, of the baseline levels. These results show that the antagonistic analog SB-75 is devoid of allergenic effects, extremely active in small doses and can be administered safely to humans. The development of sustained delivery systems for SB-75 should facilitate the clinical use of this powerful LHRH antagonist. David Gonzalez-Barcena, Hospital de Especialidades Centro Medico La Raza, Seris Y Zaachila, Col. La Raza, Mexico D.F.

The effect in post-menopausal women of natural human and artificial oestrogens on the concentration in serum of prolactin

1980 ◽  
Vol 95 (4) ◽  
pp. 433-437 ◽  
Author(s):  
Jesper Rye Andersen ◽  
Erik Schroeder ◽  
Paul Erik Lebech
Keyword(s):  
Luteinizing Hormone ◽  
Serum Concentration ◽  
Follicle Stimulating Hormone ◽  
Dose Dependence ◽  
Blood Samples ◽  
Younger Women ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Higher Doses ◽  
Stimulating Hormone

Abstract. 25 women aged 53–78 years with at least two vears menopause were divided in three groups receiving one of the following oral treatments for three weeks: 2 mg oestradiol-17β plus 1 mg oestriol, 4 mg oestradiol-17β plus 2 mg oestriol or 50 μg ethinyloestradiol daily. Blood samples were collected before, during and after the treatment and the effect on the serum concentration of prolactin, oestradiol-17β, follicle-stimulating hormone and luteinizing hormone was evaluated. During treatment with natural human oestrogens serum oestradiol-17β levels were significantly higher than before treatment. The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17β plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17β plus 2 mg oestriol or 50 μg ethinyloestradiol, thus indicating dose-dependence for natural human oestrogens. However, the increase was moderate, and these higher levels were not significantly different from levels of prolactin in serum found in 16 younger women. Concentrations of follicle-stimulating hormone and luteinizing hormon were depressed during treatment, the former to significantly lower levels when higher doses of oestrogens were used.

SHORT-TERM EFFECTS OF CASTRATION AND STARVATION UPON PITUITARY AND SERUM LEVELS OF LUTEINIZING HORMONE AND FOLLICLE STIMULATING HORMONE IN MALE RATS

1972 ◽  
Vol 70 (4) ◽  
pp. 665-675 ◽  
Author(s):  
Allen W. Root ◽  
R. David Russ
Keyword(s):  
Luteinizing Hormone ◽  
Adult Male ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Male Rats ◽  
Serum Concentrations ◽  
Short Term ◽  
Serum Lh ◽  
Total Starvation ◽  
Stimulating Hormone

ABSTRACT Serum and pituitary levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were measured by radioimmunoassay in intact and castrated juvenile (21 days) and adult male rats. The effect of total starvation upon the gonadotrophin response to castration was also investigated in adult animals. In rats castrated at 21 days of age, serum and pituitary levels of LH were elevated by 7 days and increased progressively for 4 weeks. Serum concentrations of FSH also increased within 7 days and remained stable thereafter. Pituitary FSH levels initially declined and then increased. In adult animals serum LH and FSH concentrations increased after castration. Pituitary LH values also increased, while FSH levels remained stable for 14 days after operation. Serum FSH concentrations were consistently decreased in starved-intact animals. Starvation partially inhibited castration-induced release of LH without affecting pituitary LH or FSH synthesis or FSH release.

scholarly journals Comparison of Serum Iron, Zinc, and Selenium Levels in Premenopausal and Postmenopausal Women in Ekpoma, Nigeria: A Descriptive Study

2020 ◽  
Vol 8 (2) ◽  
pp. 128-132
Author(s):  
Oloruntoba O. Festus ◽  
Solomon O. Agbebaku ◽  
Blessing O. Idonije ◽  
Olarewaju M. Oluba
Keyword(s):  
Postmenopausal Women ◽  
Serum Iron ◽  
Serum Levels ◽  
Descriptive Study ◽  
Antecubital Fossa ◽  
Pathological Conditions ◽  
Menopausal Women ◽  
Significant Difference ◽  
Post Menopausal ◽  
Age Range

Background: Estrogen deficiency following menopause creates an imbalance in plasma micronutrient resulting in several degenerative pathological conditions, including hypertension, cardiovascular disease, osteoporosis, etc. Objectives: The present study was designed to compare zinc (Zn), iron (Fe), and selenium (Se) concentrations between premenopausal and postmenopausal women. Methods: In this descriptive study a total of 200 participants were classified into two groups of postmenopausal (age range: 46-75 years, served as experimental) and premenopausal (age range: 30-45 years, served as control). Each group consisted of 100 subjects. After obtaining informed consent from all participants, blood samples were collected from the antecubital fossa vein of each participant by venipuncture. The concentrations of Fe, Zn, and Se in each blood sample were determined using Atomic Absorption Spectrophotometer. Results: No significant difference (P>0.05) was observed in serum Fe (114.24 ± 26.79 µg/dL), Zn (83.11 ± 20.45 µg/dL), and Se (41.99 ± 9.78 µg/dL) levels between the control and experimental groups. However, serum Fe and Zn showed progressive significant (P=0.04, 0.03, respectively) increase with increasing postmenopausal age. Conversely, serum Se concentration decreased significantly (P=0.03) with increasing menopausal age. Conclusion: Although no significant difference was observed in serum levels of Fe, Zn, and Se between pre- and post-menopausal women, the progressive significant increase in the serum Fe and Zn levels as well as significant decrease in serum Se level with advancing post-menopausal age portend a great risk.

Sign in / Sign up

Export Citation Format

Share Document